Deals
J&J CFO ‘Agnostic’ on Size of M&A, Looks at Deals in All Areas
- CFO says licensing deals preferred for pharma division
- ‘Very hard to do something transformational for J&J,’ he says
This article is for subscribers only.
Johnson & Johnson will consider deals of any size and for any of its three main businesses, chief financial officer Dominic Caruso said, though when it comes to pharmaceuticals the company is more interested in less-risky licensing agreements.
“We’re equally interested in all three of our businesses,” Caruso said in an interview with Bloomberg News. “We’re agnostic whether it’s big or small.” That excludes a mega-merger with another drugmaker, he said.